CTI BioPharma (CTIC)

1.99 -0.02 (1.00%)

Chart
Today 6M 1Y 5Y

Upcoming Events

- Earnings (11/5/18 *Est.)

Latest Headlines

Form 4 CTI BIOPHARMA CORP For: Sep 18 Filed by: SEELEY BRUCE J. September 20, 2018 5:27 PM - SEC Filing Form 4 CTI BIOPHARMA CORP For: Sep 18 Filed by: KIRSKE DAVID September 20, 2018 5:07 PM - SEC Filing Form 4 CTI BIOPHARMA CORP For: Sep 18 Filed by: Craig Adam R September 20, 2018 4:48 PM - SEC Filing Form 4 CTI BIOPHARMA CORP For: Sep 18 Filed by: Telling Fred September 20, 2018 4:26 PM - SEC Filing Form 8-K CTI BIOPHARMA CORP For: Sep 04 September 6, 2018 6:03 AM - SEC Filing Form 8-K CTI BIOPHARMA CORP For: Aug 14 August 15, 2018 6:09 AM - SEC Filing Form 10-Q CTI BIOPHARMA CORP For: Jun 30 August 3, 2018 6:04 AM - SEC Filing Form 8-K CTI BIOPHARMA CORP For: Aug 02 August 3, 2018 6:03 AM - SEC Filing Form 8-K CTI BIOPHARMA CORP For: Aug 02 August 2, 2018 4:02 PM - SEC Filing CTI BioPharma Reports Second Quarter 2018 Financial Results August 2, 2018 8:00 AM - PR NewsWire CTI BioPharma to Report Second Quarter 2018 Financial Results on August 2, 2018 July 26, 2018 4:01 PM - PR NewsWire Form 8-K CTI BIOPHARMA CORP For: Jul 13 July 19, 2018 6:02 AM - SEC Filing CTI BioPharma (CTIC) PT Lowered to $7 at Needham & Company July 18, 2018 12:56 PM - StreetInsider CTI BioPharma (CTIC) Reports Pacritinib Program Update Following Type B Meeting with FDA July 18, 2018 7:06 AM - StreetInsider CTI BioPharma Announces Pacritinib Program Update Following Type B Meeting with U.S. FDA July 18, 2018 7:00 AM - PR NewsWire Pre-Open Movers 07/10: (OCX) (VVUS) (XLRN) Higher; (ISR) (AQXP) (IRBT) Lower (more...) July 10, 2018 9:27 AM - StreetInsider After-Hours Stock Movers 07/09: (OCX) (XLRN) (HEAR) Higher; (AQXP) (SPRO) (WHD) Lower (more...) July 9, 2018 5:54 PM - StreetInsider CTI BioPharma (CTIC) PT Lowered to $6 at Oppenheimer July 9, 2018 9:42 AM - StreetInsider Pre-Open Movers 07/09: (MBVX) (HELE) (GRPN) Higher; (CTIC) (PETS) (PG) Lower (more...) July 9, 2018 9:00 AM - StreetInsider CTI BioPharma (CTIC) Phase III Trial Evaluating PFS of PIXUVRI Combined with Rituximab in Patients with Aggressive B-cell NHL Did Not Meet Primary Endpoint July 9, 2018 7:02 AM - StreetInsider Results of Phase III (PIX306) Trial Evaluating Progression-Free Survival of PIXUVRI® (pixantrone) Combined with Rituximab in Patients with Aggressive B-cell Non-Hodgkin Lymphoma July 9, 2018 7:00 AM - PR NewsWire CTI BioPharma (CTIC) Halted, News Pending July 9, 2018 6:55 AM - StreetInsider CTI BioPharma (CTIC) PT Raised to $7 at Oppenheimer July 9, 2018 6:29 AM - StreetInsider Form 4 CTI BIOPHARMA CORP For: Jun 30 Filed by: SEELEY BRUCE J. July 2, 2018 4:51 PM - SEC Filing CTI BioPharma (CTIC) Announces Continuation without Modification of PAC203 Phase 2 Study of Pacritinib Following IDMC Review July 2, 2018 7:02 AM - StreetInsider CTI BioPharma Announces the Continuation without Modification of PAC203 Phase 2 Study of Pacritinib in Patients with Myelofibrosis Previously Treated with Ruxolitinib July 2, 2018 7:00 AM - PR NewsWire Full Article List